Drew Lewis, MD, MTM&H, FACP

Vice President
Innoviva Specialty Therapeutics

Disclosure(s): Innoviva Specialty Therapeutics: Stocks/Bonds (Public Company)

Poster(s):

• (P-443) Population Pharmacokinetics (PPK) Analysis of Eravacycline (ERV) to Support Dose Selection for a Trial in Pediatric Patients Aged 8 to Less Than 18 Years with Complicated Intra-Abdominal Infection (cIAI)
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1206) Association of Sex Assigned at Birth and Sexual Orientation with Antimicrobial Susceptibility of Baseline Neisseria gonorrhoeae Isolates from Participants Recruited in the Global Zoliflodacin Phase 3 Randomized Controlled Trial
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET